Investment opportunity

We are looking for funding in order to move forward with our next clinical trial. Read more below.

Why invest in Medicortex Finland Oy?

TBI is the leading cause of central nervous system impairment and there is no reliable way to detect mild injuries

Medicortex is introducing, in Finland, a new diagnostic method for a huge need – detection of brain injury and concussion.

  • Our test – detecting a biomarker in a non-invasive sample (urine or saliva) – will address a TBI point of care (POC) diagnostics market that´s estimated to exceed €2 billion annually.

  • Large customer potential and variable clients

  • Current company valuation is ca. 10.6 M€.

  • Investor has an exit opportunity if the company is listed. Medicortex is pursuing a private placement during Q1 2021 in preparations for a dual listing on Nasdaq First North in Stockholm and Helsinki.

  • A team of eight people keeps the costs low and the organization lean.

  • Using professional sub-contractors with qualified track record.

  • The company has been awarded twice with an innovation prize

  • Patent applications and PCT have been filed.

Investments will be used for the clinical trial and product development.

  • Basic development including preclinical trial and proof-of-concept human testing has been done.

  • The company has completed two clinical trials where the biomarker was discovered. The first study included 24 subjects whereas the second contained 69. The recruitments were carried out in three Finnish hospitals; Tyks, Satakunta Central Hospital, Vaasa Central Hospital.

  • Currently the company is running a third clinical trial to validate the biomarker in children who have suffered a concussion. The sample collection from 29 TBI and 30 healthy subjects is completed, and the samples are currently being analyzed for the presence of the biomarker. 

Go back to Investors page